Sugi Predict

Sugi Predict / Compounds / SCHEMBL905352

SCHEMBL905352

SCHEMBL905352

COc1ccc(Cl)cc1CCl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.48
▸ HPGD P15428 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ NLRP3 Q96P20 1/20 0.44
▸ ADRB2 P07550 1/20 0.44
▸ SLC6A4 P31645 3/20 0.44
▸ SLC6A2 P23975 2/20 0.44
▸ SLC6A3 Q01959 2/20 0.44
▸ KCNH2 Q12809 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TRPV4 Q9HBA0 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12370675 0.85 IDO1 (0.50) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL2152147 0.83 TTR (0.47) TTRHPGDMEN1KMT2ASLC6A4
SCHEMBL365584 0.83 LMNA (0.51) KDM4EHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL10923464 0.83 SLC6A4 (0.49) TTRHPGDSLC6A4SLC6A2SLC6A3
SCHEMBL27996454 0.82 KDM4E (0.47) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL28091557 0.82 NLRP3 (0.47) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL712489 0.82 MAPT (0.57) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL10401199 0.82 KDM4E (0.47) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL1196055 0.82 KDM4E (0.47) TTRKDM4EHPGDSMN1; SMN2MEN1
SCHEMBL3028416 0.82 MEN1 (0.49) TTRKDM4EHPGDSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
CN-105611923-B Sodium channel modulators for the treatment of pain and diabetes 卓莫赛尔公司 2019-08-23 — — CN disclosed
US-10179781-B2 Sodium channel modulators for the treatment of pain CHROMOCELL CORPORATION 2019-01-15 — — US disclosed
US-10179781-B2 Sodium channel modulators for the treatment of pain CHROMOCELL CORPORATION 2019-01-15 — — US disclosed
WO-1999032467-A1 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-07-01 — — WO disclosed
WO-1998029407-A2 N-(PYRIDINYLAMINO)ISOINDOLINES FOR TREATING ALZHEIMER'S AND DEPRESSION HOECHST MARION ROUSSEL, INC. (US) 1998-07-09 — — WO disclosed
EP-0046590-B1 PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1985-05-22 — — EP disclosed
EP-0025192-B1 SUBSTITUTED OXIRANE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1983-05-11 — — EP disclosed
US-4337267-A HYPOKETONEMIC, HYPOGLYCEMIC, ANTIDIABETIC BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1982-06-29 — — US disclosed
US-4324796-A HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-04-13 — — US disclosed
WO-1982000643-A1 SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF BYK GULDEN LOMBERG CHEM FAB (DE) 1982-03-04 — — WO disclosed
EP-0046590-A2 Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1982-03-03 — — EP disclosed
EP-0025192-A2 Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1981-03-18 — — EP disclosed
US-3962304-A HERBICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB TTR 3424/4885KDM4E 2215/4885HPGD 1971/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB TTR 3424/4885KDM4E 2215/4885HPGD 1971/4885
US-10179781-B2 Sodium channel modulators for the treatment of pain SCN7A, SCN10A, SCN2A TTR 2226/4885KDM4E 3640/4885HPGD 767/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 TTR 1214/4885KDM4E 4324/4885HPGD 3683/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB TTR 3424/4885KDM4E 2215/4885HPGD 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.